Precipio, Inc. (PRPO)

US — Healthcare Sector
Peers: LDDD  APUS  MODD  RBOT  PLUR  MLSS  POCI  STRR  ITRM  INTS 

Automate Your Wheel Strategy on PRPO

With Tiblio's Option Bot, you can configure your own wheel strategy including PRPO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
PRPO
Published: February 25, 2026 by: GlobeNewsWire
Sentiment: Neutral

In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M

Read More
image for news Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive

PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.

Read More
image for news Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
Precipio, Inc. (PRPO) Q3 2025 Earnings Call Prepared Remarks Transcript
PRPO
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral

Precipio, Inc. ( PRPO ) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST Company Participants Ilan Danieli - Founder, President, CEO & Director Presentation Operator Welcome to the Precipio Third Quarter 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that the conference is being recorded.

Read More
image for news Precipio, Inc. (PRPO) Q3 2025 Earnings Call Prepared Remarks Transcript

About Precipio, Inc. (PRPO)

  • IPO Date 2017-06-30
  • Website https://www.precipiodx.com
  • Industry Medical - Diagnostics & Research
  • CEO Ilan Danieli
  • Employees 54
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.